Curated News
By: NewsRamp Editorial Staff
April 02, 2025
Okogen Inc. Submits Regulatory Application for Phase IIb Clinical Trial in India
TLDR
- Okogen Inc. submits regulatory application for Phase IIb clinical trial in India, gaining first-mover advantage in conjunctivitis treatment market.
- Emerald Study evaluates OKG-0303's components for bacterial and viral conjunctivitis, aligning with US FDA Guidance and training Okogen's AI platform for AIC.
- Okogen's innovative eye care solutions aim to improve accurate diagnosis and treatment of infectious conjunctivitis, benefiting patient care and limiting spread in communities.
- Dr. Hollander's appointment as CMO brings unique expertise to Okogen, pushing boundaries in ophthalmology with promising Phase IIb clinical trial and AI-enabled platform development.
Impact - Why it Matters
This news matters as Okogen's innovative approach to treating acute infectious conjunctivitis could potentially revolutionize the ophthalmology field. The appointment of Dr. Hollander and the upcoming clinical trial signify a significant step towards addressing the unmet needs of patients suffering from this condition.
Summary
Okogen Inc. announced the submission of a regulatory application to the CDSCO in India for its Phase IIb clinical trial, The Emerald Study. Dr. David A Hollander was appointed as the new CMO to lead clinical development initiatives. The study aims to evaluate OKG-0303, a triple-combination eyedrop targeting bacterial and viral conjunctivitis.
Source Statement
This curated news summary relied on this press release disributed by Reportable. Read the source press release here, Okogen Inc. Submits Regulatory Application for Phase IIb Clinical Trial in India
